>
Sea Shells, Paper or Salt As Money?
There have been no hurricanes in the Atlantic -- Yet! Making 2026 the quietest since satellite...
Tyranny by Technicality: The Supreme Court Will Not Save Our Republic
'Climate Terrorism': Manhunt Arrest in Germany Over Rocket Attacks Against High Voltage Powe
Chinese Concept Video Imagines the Future of Warfare
OPTIMUS CONFIRMED: 15,000 Bots This Year -- Tesla to $3,000
What is Going On With Robotaxi and Cybercab? Here Are All the Answers
Floating data center would provide water and electricity to 32,000 homes
OpenAI Cuts Off Elon's Cursor, Humanity's First Star Probe, and Trump's Nuclear Mars Shi
Eating pollution? Plastic-to-cookie technology raises safety, environmental concerns
Ford's $30,000 Fathom EV Truck Appears More Conventional Than Expected
Berlin-based artist Simon Weckert explored that idea with Digital Camouflage...
Tether expands tokenization business into Saudi Arabia, starting with real estate

Two adults with leukaemia have been in remission since 2010 after Car-T therapy.
It involves removing blood and genetically modifying its white cells so they target cancer.
The resulting Car-T cells are re-injected in a type of immunotherapy which uses the body's immune system to attack tumours.
Levels of the cells in the two cured patients remain high.
Dr Carl June, of the University of Pennsylvania, US, said: "Based on these results, we can conclude that Car-T cells can cure leukaemia.
"These cells continued to demonstrate tumour-killing characteristics."
Patient Doug Olsen said medics could not find any cancer after a few weeks. He said: "I knew the doctors weren't sure but I was pretty convinced that I was done with cancer."
The NHS offers Car-T to some children with leukaemia and adults with lymphoma.
It warns the therapy can make the immune system over-react or trigger side effects such as fever, vomiting or breathing difficulties.